Virtual Twins: Understanding the Data Required for Model-Informed Precision Dosing

Thomas M. Polasek; Amin Rostami-Hodjegan

doi:10.1002/cpt.1778

Virtual Twins: Understanding the Data Required for Model-Informed Precision Dosing

Thomas M. Polasek, Amin Rostami-Hodjegan

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Abstract

Physiologically‐based pharmacokinetic (PBPK) models have progressed stratified dosing in populations by accounting for attributes that affect pharmacokinetics. However, application of PBPK for model‐informed precision dosing in individual patients requires creating “virtual twins” (VTs) informed by data beyond population demographics. Some data for VTs come from routine blood tests while others are uncommon (e.g., enzyme biomarkers). Rapid growth in “liquid biopsy” technologies herald a new era where individual variations in pharmacokinetics are considered more fully.

Original language	English
Pages (from-to)	742-745
Number of pages	4
Journal	Clinical Pharmacology and Therapeutics
Volume	107
Issue number	4
DOIs	https://doi.org/10.1002/cpt.1778
Publication status	Published - 1 Apr 2020
Externally published	Yes

Keywords

Physiologically‐based pharmacokinetic (PBPK) models
pharmacokinetics
MIPD (model‐informed precision dosing)

Access to Document

10.1002/cpt.1778Licence: In Copyright

Cite this

@article{558535a9b0ab457cae4f03ca09bd4ceb,

title = "Virtual Twins: Understanding the Data Required for Model-Informed Precision Dosing",

abstract = "Physiologically‐based pharmacokinetic (PBPK) models have progressed stratified dosing in populations by accounting for attributes that affect pharmacokinetics. However, application of PBPK for model‐informed precision dosing in individual patients requires creating “virtual twins” (VTs) informed by data beyond population demographics. Some data for VTs come from routine blood tests while others are uncommon (e.g., enzyme biomarkers). Rapid growth in “liquid biopsy” technologies herald a new era where individual variations in pharmacokinetics are considered more fully.",

keywords = "Physiologically‐based pharmacokinetic (PBPK) models, pharmacokinetics, MIPD (model‐informed precision dosing)",

author = "Polasek, {Thomas M.} and Amin Rostami-Hodjegan",

year = "2020",

month = apr,

day = "1",

doi = "10.1002/cpt.1778",

language = "English",

volume = "107",

pages = "742--745",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "MOSBY",

number = "4",

}

TY - JOUR

T1 - Virtual Twins

T2 - Understanding the Data Required for Model-Informed Precision Dosing

AU - Polasek, Thomas M.

AU - Rostami-Hodjegan, Amin

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Physiologically‐based pharmacokinetic (PBPK) models have progressed stratified dosing in populations by accounting for attributes that affect pharmacokinetics. However, application of PBPK for model‐informed precision dosing in individual patients requires creating “virtual twins” (VTs) informed by data beyond population demographics. Some data for VTs come from routine blood tests while others are uncommon (e.g., enzyme biomarkers). Rapid growth in “liquid biopsy” technologies herald a new era where individual variations in pharmacokinetics are considered more fully.

AB - Physiologically‐based pharmacokinetic (PBPK) models have progressed stratified dosing in populations by accounting for attributes that affect pharmacokinetics. However, application of PBPK for model‐informed precision dosing in individual patients requires creating “virtual twins” (VTs) informed by data beyond population demographics. Some data for VTs come from routine blood tests while others are uncommon (e.g., enzyme biomarkers). Rapid growth in “liquid biopsy” technologies herald a new era where individual variations in pharmacokinetics are considered more fully.

KW - Physiologically‐based pharmacokinetic (PBPK) models

KW - pharmacokinetics

KW - MIPD (model‐informed precision dosing)

UR - http://www.scopus.com/inward/record.url?scp=85079701995&partnerID=8YFLogxK

U2 - 10.1002/cpt.1778

DO - 10.1002/cpt.1778

M3 - Article

C2 - 32056199

AN - SCOPUS:85079701995

SN - 0009-9236

VL - 107

SP - 742

EP - 745

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 4

ER -

Virtual Twins: Understanding the Data Required for Model-Informed Precision Dosing

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this